13 Nov New PRI Funding Collaboration
Posted at 17:46h in Uncategorized
We are thrilled to support the work of Mesentech, Inc. in a new funding collaborative with CureDuchenne Ventures. Together, our PRI funding will support Mesentech’s pediatric-first approach to developing its bone-targeting therapeutic, which can increase bone mass to strengthen the skeleton and holds promise for a variety of child health conditions.
Access the funding collaborative announcement from CureDuchenne Ventures here and learn more about Mesentech here.